Pilot study of a new retinoid, Ro 12-7554, in psoriasis and in some congenital disorders of keratinization.

Ro12-7554, a chlorinated derivative of etretinate, was evaluated in an open study. 16 patients, 13 suffering from severe psoriasis and 3 from congenital disorders of keratinization previously treated with etretinate, received Ro 12-7554 at a mean daily dosage of 12.3 mg/day. Ro 12-7554 was very similar to etretinate in terms of clinical efficacy and overall safety.